<?xml version="1.0" encoding="utf-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="2007-09-11" modified="2020-10-07" version="163">
<accession>O15357</accession>
<accession>B2RTX5</accession>
<accession>Q13577</accession>
<accession>Q13578</accession>
<name>SHIP2_HUMAN</name>
<protein>
<recommendedName>
<fullName evidence="46">Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2</fullName>
<ecNumber evidence="16 33 43">3.1.3.86</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Inositol polyphosphate phosphatase-like protein 1</fullName>
<shortName>INPPL-1</shortName>
</alternativeName>
<alternativeName>
<fullName>Protein 51C</fullName>
</alternativeName>
<alternativeName>
<fullName>SH2 domain-containing inositol 5'-phosphatase 2</fullName>
<shortName>SH2 domain-containing inositol phosphatase 2</shortName>
<shortName>SHIP-2</shortName>
</alternativeName>
</protein>
<gene>
<name type="primary">INPPL1</name>
<name type="synonym">SHIP2</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1995" name="Genomics" volume="29" first="285" last="287">
<title>Cloning and characterization of a human cDNA (INPPL1) sharing homology with inositol polyphosphate phosphatases.</title>
<authorList>
<person name="Hejna J.A."/>
<person name="Saito H."/>
<person name="Merkens L.S."/>
<person name="Tittle T.V."/>
<person name="Jakobs P.M."/>
<person name="Whitney M.A."/>
<person name="Grompe M."/>
<person name="Friedberg A.S."/>
<person name="Moses R.E."/>
</authorList>
<dbReference type="PubMed" id="8530088"/>
<dbReference type="DOI" id="10.1006/geno.1995.1247"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1997" name="Biochem. Biophys. Res. Commun." volume="239" first="697" last="700">
<title>Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP.</title>
<authorList>
<person name="Pesesse X."/>
<person name="Deleu S."/>
<person name="De Smedt F."/>
<person name="Drayer L."/>
<person name="Erneux C."/>
</authorList>
<dbReference type="PubMed" id="9367831"/>
<dbReference type="DOI" id="10.1006/bbrc.1997.7538"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>VARIANT GLY-1114</scope>
<source>
<tissue>Hippocampus</tissue>
</source>
</reference>
<reference key="3">
<citation type="journal article" date="2006" name="Nature" volume="440" first="497" last="500">
<title>Human chromosome 11 DNA sequence and analysis including novel gene identification.</title>
<authorList>
<person name="Taylor T.D."/>
<person name="Noguchi H."/>
<person name="Totoki Y."/>
<person name="Toyoda A."/>
<person name="Kuroki Y."/>
<person name="Dewar K."/>
<person name="Lloyd C."/>
<person name="Itoh T."/>
<person name="Takeda T."/>
<person name="Kim D.-W."/>
<person name="She X."/>
<person name="Barlow K.F."/>
<person name="Bloom T."/>
<person name="Bruford E."/>
<person name="Chang J.L."/>
<person name="Cuomo C.A."/>
<person name="Eichler E."/>
<person name="FitzGerald M.G."/>
<person name="Jaffe D.B."/>
<person name="LaButti K."/>
<person name="Nicol R."/>
<person name="Park H.-S."/>
<person name="Seaman C."/>
<person name="Sougnez C."/>
<person name="Yang X."/>
<person name="Zimmer A.R."/>
<person name="Zody M.C."/>
<person name="Birren B.W."/>
<person name="Nusbaum C."/>
<person name="Fujiyama A."/>
<person name="Hattori M."/>
<person name="Rogers J."/>
<person name="Lander E.S."/>
<person name="Sakaki Y."/>
</authorList>
<dbReference type="PubMed" id="16554811"/>
<dbReference type="DOI" id="10.1038/nature04632"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="4">
<citation type="submission" date="2005-07" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Mural R.J."/>
<person name="Istrail S."/>
<person name="Sutton G.G."/>
<person name="Florea L."/>
<person name="Halpern A.L."/>
<person name="Mobarry C.M."/>
<person name="Lippert R."/>
<person name="Walenz B."/>
<person name="Shatkay H."/>
<person name="Dew I."/>
<person name="Miller J.R."/>
<person name="Flanigan M.J."/>
<person name="Edwards N.J."/>
<person name="Bolanos R."/>
<person name="Fasulo D."/>
<person name="Halldorsson B.V."/>
<person name="Hannenhalli S."/>
<person name="Turner R."/>
<person name="Yooseph S."/>
<person name="Lu F."/>
<person name="Nusskern D.R."/>
<person name="Shue B.C."/>
<person name="Zheng X.H."/>
<person name="Zhong F."/>
<person name="Delcher A.L."/>
<person name="Huson D.H."/>
<person name="Kravitz S.A."/>
<person name="Mouchard L."/>
<person name="Reinert K."/>
<person name="Remington K.A."/>
<person name="Clark A.G."/>
<person name="Waterman M.S."/>
<person name="Eichler E.E."/>
<person name="Adams M.D."/>
<person name="Hunkapiller M.W."/>
<person name="Myers E.W."/>
<person name="Venter J.C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
<scope>VARIANT GLY-1114</scope>
</reference>
<reference key="5">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)</scope>
<scope>VARIANT GLY-1114</scope>
</reference>
<reference key="6">
<citation type="journal article" date="1998" name="J. Biol. Chem." volume="273" first="18605" last="18609">
<title>Growth factors and insulin stimulate tyrosine phosphorylation of the 51C/SHIP2 protein.</title>
<authorList>
<person name="Habib T."/>
<person name="Hejna J.A."/>
<person name="Moses R.E."/>
<person name="Decker S.J."/>
</authorList>
<dbReference type="PubMed" id="9660833"/>
<dbReference type="DOI" id="10.1074/jbc.273.29.18605"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>PHOSPHORYLATION</scope>
<scope>INTERACTION WITH SHC1</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1999" name="Blood" volume="93" first="2707" last="2720">
<title>A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.</title>
<authorList>
<person name="Wisniewski D."/>
<person name="Strife A."/>
<person name="Swendeman S."/>
<person name="Erdjument-Bromage H."/>
<person name="Geromanos S."/>
<person name="Kavanaugh W.M."/>
<person name="Tempst P."/>
<person name="Clarkson B."/>
</authorList>
<dbReference type="PubMed" id="10194451"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>PHOSPHORYLATION</scope>
<scope>INTERACTION WITH SHC1 AND ABL1</scope>
</reference>
<reference key="8">
<citation type="journal article" date="2000" name="J. Biol. Chem." volume="275" first="37357" last="37364">
<title>Molecular basis of the recruitment of the SH2 domain-containing inositol 5-phosphatases SHIP1 and SHIP2 by fcgamma RIIB.</title>
<authorList>
<person name="Bruhns P."/>
<person name="Vely F."/>
<person name="Malbec O."/>
<person name="Fridman W.H."/>
<person name="Vivier E."/>
<person name="Daeeron M."/>
</authorList>
<dbReference type="PubMed" id="11016922"/>
<dbReference type="DOI" id="10.1074/jbc.m003518200"/>
</citation>
<scope>INTERACTION WITH FCGR2B</scope>
</reference>
<reference key="9">
<citation type="journal article" date="2001" name="J. Biol. Chem." volume="276" first="28348" last="28355">
<title>The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is recruited to the epidermal growth factor (EGF) receptor and dephosphorylates phosphatidylinositol 3,4,5-trisphosphate in EGF-stimulated COS-7 cells.</title>
<authorList>
<person name="Pesesse X."/>
<person name="Dewaste V."/>
<person name="De Smedt F."/>
<person name="Laffargue M."/>
<person name="Giuriato S."/>
<person name="Moreau C."/>
<person name="Payrastre B."/>
<person name="Erneux C."/>
</authorList>
<dbReference type="PubMed" id="11349134"/>
<dbReference type="DOI" id="10.1074/jbc.m103537200"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH EGFR AND SHC1</scope>
<scope>PHOSPHORYLATION AT TYR-986</scope>
</reference>
<reference key="10">
<citation type="journal article" date="2001" name="J. Cell Biol." volume="155" first="1065" last="1079">
<title>The SH2-containing inositol polyphosphate 5-phosphatase, SHIP-2, binds filamin and regulates submembraneous actin.</title>
<authorList>
<person name="Dyson J.M."/>
<person name="O'Malley C.J."/>
<person name="Becanovic J."/>
<person name="Munday A.D."/>
<person name="Berndt M.C."/>
<person name="Coghill I.D."/>
<person name="Nandurkar H.H."/>
<person name="Ooms L.M."/>
<person name="Mitchell C.A."/>
</authorList>
<dbReference type="PubMed" id="11739414"/>
<dbReference type="DOI" id="10.1083/jcb.200104005"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH FLNA AND FLNB</scope>
</reference>
<reference key="11">
<citation type="journal article" date="2001" name="Mol. Cell. Biol." volume="21" first="1416" last="1428">
<title>SH2-containing inositol 5'-phosphatase SHIP2 associates with the p130(Cas) adapter protein and regulates cellular adhesion and spreading.</title>
<authorList>
<person name="Prasad N."/>
<person name="Topping R.S."/>
<person name="Decker S.J."/>
</authorList>
<dbReference type="PubMed" id="11158326"/>
<dbReference type="DOI" id="10.1128/mcb.21.4.1416-1428.2001"/>
</citation>
<scope>PHOSPHORYLATION</scope>
<scope>INTERACTION WITH BCAR1</scope>
<scope>MUTAGENESIS OF ARG-47</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="1031" last="1039">
<title>Tyrosine phosphorylation mapping of the epidermal growth factor receptor signaling pathway.</title>
<authorList>
<person name="Steen H."/>
<person name="Kuster B."/>
<person name="Fernandez M."/>
<person name="Pandey A."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="11687594"/>
<dbReference type="DOI" id="10.1074/jbc.m109992200"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-1162</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2002" name="J. Cell Sci." volume="115" first="3807" last="3815">
<title>Src family tyrosine kinases regulate adhesion-dependent tyrosine phosphorylation of 5'-inositol phosphatase SHIP2 during cell attachment and spreading on collagen I.</title>
<authorList>
<person name="Prasad N."/>
<person name="Topping R.S."/>
<person name="Decker S.J."/>
</authorList>
<dbReference type="PubMed" id="12235291"/>
<dbReference type="DOI" id="10.1242/jcs.00070"/>
</citation>
<scope>FUNCTION</scope>
<scope>PHOSPHORYLATION AT TYR-986</scope>
<scope>MUTAGENESIS OF 986-TYR-TYR-987</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2003" name="Biochem. Biophys. Res. Commun." volume="300" first="494" last="500">
<title>The c-Cbl-associated protein and c-Cbl are two new partners of the SH2-containing inositol polyphosphate 5-phosphatase SHIP2.</title>
<authorList>
<person name="Vandenbroere I."/>
<person name="Paternotte N."/>
<person name="Dumont J.E."/>
<person name="Erneux C."/>
<person name="Pirson I."/>
</authorList>
<dbReference type="PubMed" id="12504111"/>
<dbReference type="DOI" id="10.1016/s0006-291x(02)02894-2"/>
</citation>
<scope>INTERACTION WITH CBL AND SORBS1</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2003" name="Blood" volume="102" first="940" last="948">
<title>SHIP-2 forms a tetrameric complex with filamin, actin, and GPIb-IX-V: localization of SHIP-2 to the activated platelet actin cytoskeleton.</title>
<authorList>
<person name="Dyson J.M."/>
<person name="Munday A.D."/>
<person name="Kong A.M."/>
<person name="Huysmans R.D."/>
<person name="Matzaris M."/>
<person name="Layton M.J."/>
<person name="Nandurkar H.H."/>
<person name="Berndt M.C."/>
<person name="Mitchell C.A."/>
</authorList>
<dbReference type="PubMed" id="12676785"/>
<dbReference type="DOI" id="10.1182/blood-2002-09-2897"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>INTERACTION WITH ACTIN; FILAMIN AND GPIB</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="22657" last="22663">
<title>SHIP-2 inositol phosphatase is inducibly expressed in human monocytes and serves to regulate Fcgamma receptor-mediated signaling.</title>
<authorList>
<person name="Pengal R.A."/>
<person name="Ganesan L.P."/>
<person name="Fang H."/>
<person name="Marsh C.B."/>
<person name="Anderson C.L."/>
<person name="Tridandapani S."/>
</authorList>
<dbReference type="PubMed" id="12690104"/>
<dbReference type="DOI" id="10.1074/jbc.m302907200"/>
</citation>
<scope>FUNCTION</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>INDUCTION</scope>
<scope>PHOSPHORYLATION</scope>
<scope>INTERACTION WITH FCGR2A</scope>
<scope>MUTAGENESIS OF ARG-47 AND ASP-607</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2005" name="Nat. Biotechnol." volume="23" first="94" last="101">
<title>Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.</title>
<authorList>
<person name="Rush J."/>
<person name="Moritz A."/>
<person name="Lee K.A."/>
<person name="Guo A."/>
<person name="Goss V.L."/>
<person name="Spek E.J."/>
<person name="Zhang H."/>
<person name="Zha X.-M."/>
<person name="Polakiewicz R.D."/>
<person name="Comb M.J."/>
</authorList>
<dbReference type="PubMed" id="15592455"/>
<dbReference type="DOI" id="10.1038/nbt1046"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2006" name="Cell" volume="127" first="635" last="648">
<title>Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
<person name="Gnad F."/>
<person name="Macek B."/>
<person name="Kumar C."/>
<person name="Mortensen P."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="17081983"/>
<dbReference type="DOI" id="10.1016/j.cell.2006.09.026"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1135</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="19">
<citation type="journal article" date="2006" name="Cell. Signal." volume="18" first="2193" last="2199">
<title>The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase activity.</title>
<authorList>
<person name="Vandeput F."/>
<person name="Backers K."/>
<person name="Villeret V."/>
<person name="Pesesse X."/>
<person name="Erneux C."/>
</authorList>
<dbReference type="PubMed" id="16824732"/>
<dbReference type="DOI" id="10.1016/j.cellsig.2006.05.010"/>
</citation>
<scope>ACTIVITY REGULATION</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2005" name="FEBS J." volume="272" first="6052" last="6066">
<title>SHIP2 interaction with the cytoskeletal protein Vinexin.</title>
<authorList>
<person name="Paternotte N."/>
<person name="Zhang J."/>
<person name="Vandenbroere I."/>
<person name="Backers K."/>
<person name="Blero D."/>
<person name="Kioka N."/>
<person name="Vanderwinden J.-M."/>
<person name="Pirson I."/>
<person name="Erneux C."/>
</authorList>
<dbReference type="PubMed" id="16302969"/>
<dbReference type="DOI" id="10.1111/j.1742-4658.2005.04996.x"/>
</citation>
<scope>INTERACTION WITH SORBS3</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2005" name="J. Biol. Chem." volume="280" first="13129" last="13136">
<title>SH2-containing 5'-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor.</title>
<authorList>
<person name="Prasad N.K."/>
<person name="Decker S.J."/>
</authorList>
<dbReference type="PubMed" id="15668240"/>
<dbReference type="DOI" id="10.1074/jbc.m410289200"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2005" name="Oncogene" volume="24" first="3436" last="3447">
<title>The SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading.</title>
<authorList>
<person name="Koch A."/>
<person name="Mancini A."/>
<person name="El Bounkari O."/>
<person name="Tamura T."/>
</authorList>
<dbReference type="PubMed" id="15735664"/>
<dbReference type="DOI" id="10.1038/sj.onc.1208558"/>
</citation>
<scope>INTERACTION WITH MET</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2007" name="Cell. Signal." volume="19" first="1249" last="1257">
<title>The PI3K effector Arap3 interacts with the PI(3,4,5)P3 phosphatase SHIP2 in a SAM domain-dependent manner.</title>
<authorList>
<person name="Raaijmakers J.H."/>
<person name="Deneubourg L."/>
<person name="Rehmann H."/>
<person name="de Koning J."/>
<person name="Zhang Z."/>
<person name="Krugmann S."/>
<person name="Erneux C."/>
<person name="Bos J.L."/>
</authorList>
<dbReference type="PubMed" id="17314030"/>
<dbReference type="DOI" id="10.1016/j.cellsig.2006.12.015"/>
</citation>
<scope>INTERACTION WITH CENTD3</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2007" name="J. Biol. Chem." volume="282" first="2683" last="2694">
<title>Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation.</title>
<authorList>
<person name="Zhuang G."/>
<person name="Hunter S."/>
<person name="Hwang Y."/>
<person name="Chen J."/>
</authorList>
<dbReference type="PubMed" id="17135240"/>
<dbReference type="DOI" id="10.1074/jbc.m608509200"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH EPHA2</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2007" name="J. Cell. Physiol." volume="211" first="598" last="607">
<title>Regulation of PDGF-stimulated SHIP2 tyrosine phosphorylation and association with Shc in 3T3-L1 preadipocytes.</title>
<authorList>
<person name="Artemenko Y."/>
<person name="Gagnon A."/>
<person name="Ibrahim S."/>
<person name="Sorisky A."/>
</authorList>
<dbReference type="PubMed" id="17219406"/>
<dbReference type="DOI" id="10.1002/jcp.20965"/>
</citation>
<scope>PHOSPHORYLATION AT THR-958</scope>
<scope>MUTAGENESIS OF THR-958</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2002" name="Diabetes" volume="51" first="2012" last="2017">
<title>The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man.</title>
<authorList>
<person name="Marion E."/>
<person name="Kaisaki P.J."/>
<person name="Pouillon V."/>
<person name="Gueydan C."/>
<person name="Levy J.C."/>
<person name="Bodson A."/>
<person name="Krzentowski G."/>
<person name="Daubresse J.-C."/>
<person name="Mockel J."/>
<person name="Behrends J."/>
<person name="Servais G."/>
<person name="Szpirer C."/>
<person name="Kruys V."/>
<person name="Gauguier D."/>
<person name="Schurmans S."/>
</authorList>
<dbReference type="PubMed" id="12086927"/>
<dbReference type="DOI" id="10.2337/diabetes.51.7.2012"/>
</citation>
<scope>INVOLVEMENT IN NIDDM</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2004" name="Diabetes" volume="53" first="1900" last="1904">
<title>Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome.</title>
<authorList>
<person name="Kaisaki P.J."/>
<person name="Delepine M."/>
<person name="Woon P.Y."/>
<person name="Sebag-Montefiore L."/>
<person name="Wilder S.P."/>
<person name="Menzel S."/>
<person name="Vionnet N."/>
<person name="Marion E."/>
<person name="Riveline J.-P."/>
<person name="Charpentier G."/>
<person name="Schurmans S."/>
<person name="Levy J.C."/>
<person name="Lathrop M."/>
<person name="Farrall M."/>
<person name="Gauguier D."/>
</authorList>
<dbReference type="PubMed" id="15220217"/>
<dbReference type="DOI" id="10.2337/diabetes.53.7.1900"/>
</citation>
<scope>INVOLVEMENT IN METABOLIC SYNDROME</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2005" name="J. Clin. Endocrinol. Metab." volume="90" first="2911" last="2919">
<title>Impact of SRC homology 2-containing inositol 5'-phosphatase 2 gene polymorphisms detected in a Japanese population on insulin signaling.</title>
<authorList>
<person name="Kagawa S."/>
<person name="Sasaoka T."/>
<person name="Yaguchi S."/>
<person name="Ishihara H."/>
<person name="Tsuneki H."/>
<person name="Murakami S."/>
<person name="Fukui K."/>
<person name="Wada T."/>
<person name="Kobayashi S."/>
<person name="Kimura I."/>
<person name="Kobayashi M."/>
</authorList>
<dbReference type="PubMed" id="15687335"/>
<dbReference type="DOI" id="10.1210/jc.2004-1724"/>
</citation>
<scope>INVOLVEMENT IN NIDDM</scope>
<scope>VARIANTS ILE-632; MET-721; SER-982 AND GLY-1083</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2007" name="J. Med. Genet." volume="44" first="603" last="605">
<title>Genetic association analysis of inositol polyphosphate phosphatase-like 1 (INPPL1, SHIP2) variants with essential hypertension.</title>
<authorList>
<person name="Braga Marcano A.C."/>
<person name="Burke B."/>
<person name="Gungadoo J."/>
<person name="Wallace C."/>
<person name="Kaisaki P.J."/>
<person name="Woon P.Y."/>
<person name="Farrall M."/>
<person name="Clayton D."/>
<person name="Brown M."/>
<person name="Dominiczak A."/>
<person name="Connell J.M."/>
<person name="Webster J."/>
<person name="Lathrop M."/>
<person name="Caulfield M."/>
<person name="Samani N."/>
<person name="Gauguier D."/>
<person name="Munroe P.B."/>
</authorList>
<dbReference type="PubMed" id="17557929"/>
<dbReference type="DOI" id="10.1136/jmg.2007.049718"/>
</citation>
<scope>INVOLVEMENT IN METABOLIC SYNDROME</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2008" name="Mol. Cell" volume="31" first="438" last="448">
<title>Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.</title>
<authorList>
<person name="Daub H."/>
<person name="Olsen J.V."/>
<person name="Bairlein M."/>
<person name="Gnad F."/>
<person name="Oppermann F.S."/>
<person name="Korner R."/>
<person name="Greff Z."/>
<person name="Keri G."/>
<person name="Stemmann O."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="18691976"/>
<dbReference type="DOI" id="10.1016/j.molcel.2008.07.007"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="31">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-165 AND SER-241</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="32">
<citation type="journal article" date="2010" name="Sci. Signal." volume="3" first="RA3" last="RA3">
<title>Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Vermeulen M."/>
<person name="Santamaria A."/>
<person name="Kumar C."/>
<person name="Miller M.L."/>
<person name="Jensen L.J."/>
<person name="Gnad F."/>
<person name="Cox J."/>
<person name="Jensen T.S."/>
<person name="Nigg E.A."/>
<person name="Brunak S."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="20068231"/>
<dbReference type="DOI" id="10.1126/scisignal.2000475"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="33">
<citation type="journal article" date="2011" name="BMC Syst. Biol." volume="5" first="17" last="17">
<title>Initial characterization of the human central proteome.</title>
<authorList>
<person name="Burkard T.R."/>
<person name="Planyavsky M."/>
<person name="Kaupe I."/>
<person name="Breitwieser F.P."/>
<person name="Buerckstuemmer T."/>
<person name="Bennett K.L."/>
<person name="Superti-Furga G."/>
<person name="Colinge J."/>
</authorList>
<dbReference type="PubMed" id="21269460"/>
<dbReference type="DOI" id="10.1186/1752-0509-5-17"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2011" name="Immunol. Lett." volume="134" first="174" last="182">
<title>FCRL6 receptor: expression and associated proteins.</title>
<authorList>
<person name="Kulemzin S.V."/>
<person name="Zamoshnikova A.Y."/>
<person name="Yurchenko M.Y."/>
<person name="Vitak N.Y."/>
<person name="Najakshin A.M."/>
<person name="Fayngerts S.A."/>
<person name="Chikaev N.A."/>
<person name="Reshetnikova E.S."/>
<person name="Kashirina N.M."/>
<person name="Peclo M.M."/>
<person name="Rutkevich P.N."/>
<person name="Shevelev A.Y."/>
<person name="Yanushevskaya E.V."/>
<person name="Baranov K.O."/>
<person name="Mamonkin M."/>
<person name="Vlasik T.N."/>
<person name="Sidorenko S.P."/>
<person name="Taranin A.V."/>
<person name="Mechetina L.V."/>
</authorList>
<dbReference type="PubMed" id="20933011"/>
<dbReference type="DOI" id="10.1016/j.imlet.2010.09.023"/>
</citation>
<scope>INTERACTION WITH FCRL6</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2011" name="J. Cell Biol." volume="193" first="901" last="916">
<title>SH3YL1 regulates dorsal ruffle formation by a novel phosphoinositide-binding domain.</title>
<authorList>
<person name="Hasegawa J."/>
<person name="Tokuda E."/>
<person name="Tenno T."/>
<person name="Tsujita K."/>
<person name="Sawai H."/>
<person name="Hiroaki H."/>
<person name="Takenawa T."/>
<person name="Itoh T."/>
</authorList>
<dbReference type="PubMed" id="21624956"/>
<dbReference type="DOI" id="10.1083/jcb.201012161"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH SH3YL1</scope>
<scope>MUTAGENESIS OF 140-PRO-LEU-141</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2013" name="Am. J. Hum. Genet." volume="92" first="144" last="149">
<title>Exome sequencing identifies INPPL1 mutations as a cause of opsismodysplasia.</title>
<authorList>
<person name="Huber C."/>
<person name="Faqeih E.A."/>
<person name="Bartholdi D."/>
<person name="Bole-Feysot C."/>
<person name="Borochowitz Z."/>
<person name="Cavalcanti D.P."/>
<person name="Frigo A."/>
<person name="Nitschke P."/>
<person name="Roume J."/>
<person name="Santos H.G."/>
<person name="Shalev S.A."/>
<person name="Superti-Furga A."/>
<person name="Delezoide A.L."/>
<person name="Le Merrer M."/>
<person name="Munnich A."/>
<person name="Cormier-Daire V."/>
</authorList>
<dbReference type="PubMed" id="23273569"/>
<dbReference type="DOI" id="10.1016/j.ajhg.2012.11.015"/>
</citation>
<scope>FUNCTION</scope>
<scope>VARIANTS OPSMD TRP-401; SER-659; CYS-688 AND ILE-722</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-132; SER-352; TYR-886; SER-890; THR-958; SER-1131; TYR-1135; TYR-1162 AND SER-1257</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<comment type="function">
<text evidence="19 21 23 25 26 29 33 34 39 40 43">Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways. Plays a central role in regulation of PI3K-dependent insulin signaling, although the precise molecular mechanisms and signaling pathways remain unclear. While overexpression reduces both insulin-stimulated MAP kinase and Akt activation, its absence does not affect insulin signaling or GLUT4 trafficking. Confers resistance to dietary obesity. May act by regulating AKT2, but not AKT1, phosphorylation at the plasma membrane. Part of a signaling pathway that regulates actin cytoskeleton remodeling. Required for the maintenance and dynamic remodeling of actin structures as well as in endocytosis, having a major impact on ligand-induced EGFR internalization and degradation. Participates in regulation of cortical and submembraneous actin by hydrolyzing PtdIns(3,4,5)P3 thereby regulating membrane ruffling (PubMed:21624956). Regulates cell adhesion and cell spreading. Required for HGF-mediated lamellipodium formation, cell scattering and spreading. Acts as a negative regulator of EPHA2 receptor endocytosis by inhibiting via PI3K-dependent Rac1 activation. Acts as a regulator of neuritogenesis by regulating PtdIns(3,4,5)P3 level and is required to form an initial protrusive pattern, and later, maintain proper neurite outgrowth. Acts as a negative regulator of the FC-gamma-RIIA receptor (FCGR2A). Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B), playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems. Involved in EGF signaling pathway. Upon stimulation by EGF, it is recruited by EGFR and dephosphorylates PtdIns(3,4,5)P3. Plays a negative role in regulating the PI3K-PKB pathway, possibly by inhibiting PKB activity. Down-regulates Fc-gamma-R-mediated phagocytosis in macrophages independently of INPP5D/SHIP1. In macrophages, down-regulates NF-kappa-B-dependent gene transcription by regulating macrophage colony-stimulating factor (M-CSF)-induced signaling. May also hydrolyze PtdIns(1,3,4,5)P4, and could thus affect the levels of the higher inositol polyphosphates like InsP6. Involved in endochondral ossification.</text>
</comment>
<comment type="catalytic activity">
<reaction evidence="16 33 43">
<text>a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) + phosphate</text>
<dbReference type="Rhea" id="RHEA:25528"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:43474"/>
<dbReference type="ChEBI" id="CHEBI:57658"/>
<dbReference type="ChEBI" id="CHEBI:57836"/>
<dbReference type="EC" id="3.1.3.86"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="47">
<dbReference type="Rhea" id="RHEA:25529"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="33">
<text>1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) + phosphate</text>
<dbReference type="Rhea" id="RHEA:43548"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:43474"/>
<dbReference type="ChEBI" id="CHEBI:83416"/>
<dbReference type="ChEBI" id="CHEBI:83417"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="48">
<dbReference type="Rhea" id="RHEA:43549"/>
</physiologicalReaction>
</comment>
<comment type="catalytic activity">
<reaction evidence="33">
<text>1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) + phosphate</text>
<dbReference type="Rhea" id="RHEA:43556"/>
<dbReference type="ChEBI" id="CHEBI:15377"/>
<dbReference type="ChEBI" id="CHEBI:43474"/>
<dbReference type="ChEBI" id="CHEBI:83420"/>
<dbReference type="ChEBI" id="CHEBI:83422"/>
</reaction>
<physiologicalReaction direction="left-to-right" evidence="48">
<dbReference type="Rhea" id="RHEA:43557"/>
</physiologicalReaction>
</comment>
<comment type="activity regulation">
<text evidence="33">Activated upon translocation to the sites of synthesis of PtdIns(3,4,5)P3 in the membrane. Enzymatic activity is enhanced in the presence of phosphatidylserine.</text>
</comment>
<comment type="subunit">
<text evidence="13 16 17 18 19 21 24 25 26 31 32 34 36 38 43">Interacts with tyrosine phosphorylated form of SHC1 (PubMed:9660833, PubMed:10194451, PubMed:11349134). Interacts with EGFR (PubMed:11349134). Upon stimulation by the EGF signaling pathway, it forms a complex with SHC1 and EGFR (PubMed:11349134). Interacts with cytoskeletal protein SORBS3/vinexin, promoting its localization to the periphery of cells (PubMed:16302969). Forms a complex with filamin (FLNA or FLNB), actin, GPIb (GP1BA or GP1BB) that regulates cortical and submembraneous actin (PubMed:11739414, PubMed:12676785). Interacts with c-Met/MET, when c-Met/MET is phosphorylated on 'Tyr-1356' (PubMed:15735664). Interacts with p130Cas/BCAR1 (PubMed:11158326). Interacts with CENTD3/ARAP3 via its SAM domain (PubMed:17314030). Interacts with c-Cbl/CBL and CAP/SORBS1 (PubMed:12504111). Interacts with activated EPHA2 receptor (PubMed:17135240). Interacts with receptor FCGR2A (PubMed:12690104). Interacts with receptor FCGR2B (PubMed:11016922). Interacts with tyrosine kinase ABL1 (PubMed:10194451). Interacts with tyrosine kinase TEC (By similarity). Interacts with CSF1R (By similarity). Interacts (via N-terminus) with SH3YL1 (via SH3 domain) (PubMed:21624956). Interacts with FCRL6 (tyrosine phosphorylated form) (PubMed:20933011).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1384248">
<id>O15357</id>
</interactant>
<interactant intactId="EBI-608057">
<id>P10275</id>
<label>AR</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1384248">
<id>O15357</id>
</interactant>
<interactant intactId="EBI-702093">
<id>P56945</id>
<label>BCAR1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1384248">
<id>O15357</id>
</interactant>
<interactant intactId="EBI-517684">
<id>Q13480</id>
<label>GAB1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1384248">
<id>O15357</id>
</interactant>
<interactant intactId="EBI-743438">
<id>Q8IV36</id>
<label>HID1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1384248">
<id>O15357</id>
</interactant>
<interactant intactId="EBI-8052395">
<id>Q15811-2</id>
<label>ITSN1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>9</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1384248">
<id>O15357</id>
</interactant>
<interactant intactId="EBI-1039152">
<id>P08581</id>
<label>MET</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1384248">
<id>O15357</id>
</interactant>
<interactant intactId="EBI-433642">
<id>Q9BX66</id>
<label>SORBS1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1384248">
<id>O15357</id>
</interactant>
<interactant intactId="EBI-1222953">
<id>O60504-1</id>
<label>SORBS3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1384248">
<id>O15357</id>
</interactant>
<interactant intactId="EBI-2504267">
<id>A0A061I5T4</id>
<label>H671_4g13114</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-15963021">
<id>O15357-1</id>
</interactant>
<interactant intactId="EBI-702104">
<id>P29317</id>
<label>EPHA2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="19">Cytoplasm</location>
<location evidence="19">Cytosol</location>
</subcellularLocation>
<subcellularLocation>
<location>Cytoplasm</location>
<location>Cytoskeleton</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="21">Membrane</location>
<topology>Peripheral membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location evidence="25">Cell projection</location>
<location evidence="25">Filopodium</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="25">Cell projection</location>
<location evidence="25">Lamellipodium</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="12">Nucleus</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="12">Nucleus speckle</location>
</subcellularLocation>
<text>Translocates to membrane ruffles when activated, translocation is probably due to different mechanisms depending on the stimulus and cell type. Partly translocated via its SH2 domain which mediates interaction with tyrosine phosphorylated receptors such as the FC-gamma-RIIB receptor (FCGR2B). Tyrosine phosphorylation may also participate in membrane localization. Insulin specifically stimulates its redistribution from the cytosol to the plasma membrane. Recruited to the membrane following M-CSF stimulation. In activated spreading platelets, localizes with actin at filopodia, lamellipodia and the central actin ring.</text>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>O15357-1</id>
<name>1</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>O15357-2</id>
<name>2</name>
<sequence type="described" ref="VSP_027985"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="25 26 41 42 43">Widely expressed, most prominently in skeletal muscle, heart and brain. Present in platelets. Expressed in transformed myeloid cells and in primary macrophages, but not in peripheral blood monocytes.</text>
</comment>
<comment type="induction">
<text evidence="26">By bacterial lipopolysaccharides (LPS).</text>
</comment>
<comment type="domain">
<text>The SH2 domain interacts with tyrosine phosphorylated forms of proteins such as SHC1 or FCGR2A. It also mediates the interaction with p130Cas/BCAR1.</text>
</comment>
<comment type="domain">
<text evidence="11">The NPXY sequence motif found in many tyrosine-phosphorylated proteins is required for the specific binding of the PID domain.</text>
</comment>
<comment type="PTM">
<text evidence="16 18 19 20 23 26 35 43">Tyrosine phosphorylated by the members of the SRC family after exposure to a diverse array of extracellular stimuli such as insulin, growth factors such as EGF or PDGF, chemokines, integrin ligands and hypertonic and oxidative stress. May be phosphorylated upon IgG receptor FCGR2B-binding. Phosphorylated at Tyr-986 following cell attachment and spreading. Phosphorylated at Tyr-1162 following EGF signaling pathway stimulation. Phosphorylated at Thr-958 in response to PDGF.</text>
</comment>
<comment type="disease" evidence="22 30">
<disease id="DI-02060">
<name>Diabetes mellitus, non-insulin-dependent</name>
<acronym>NIDDM</acronym>
<description>A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.</description>
<dbReference type="MIM" id="125853"/>
</disease>
<text>Disease susceptibility may be associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease">
<text evidence="27 37">Genetic variations in INPPL1 may be a cause of susceptibility to metabolic syndrome. Metabolic syndrome is characterized by diabetes, insulin resistance, hypertension, and hypertriglyceridemia is absent.</text>
</comment>
<comment type="disease" evidence="40">
<disease id="DI-03691">
<name>Opsismodysplasia</name>
<acronym>OPSMD</acronym>
<description>A rare skeletal dysplasia involving delayed bone maturation. Clinical signs observed at birth include short limbs, small hands and feet, relative macrocephaly with a large anterior fontanel, and characteristic craniofacial abnormalities including a prominent brow, depressed nasal bridge, a small anteverted nose, and a relatively long philtrum. Death secondary to respiratory failure during the first few years of life has been reported, but there can be long-term survival. Typical radiographic findings include shortened long bones with very delayed epiphyseal ossification, severe platyspondyly, metaphyseal cupping, and characteristic abnormalities of the metacarpals and phalanges.</description>
<dbReference type="MIM" id="258480"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="miscellaneous">
<text>Its ability to confer resistance to dietary obesity suggests that it may serve as a possible therapeutic target in cases of type 2 diabetes and obesity.</text>
</comment>
<comment type="similarity">
<text evidence="46">Belongs to the inositol 1,4,5-trisphosphate 5-phosphatase family.</text>
</comment>
<comment type="sequence caution" evidence="46">
<conflict type="frameshift">
<sequence resource="EMBL-CDS" id="AAA50503" version="1"/>
</conflict>
</comment>
<comment type="sequence caution" evidence="46">
<conflict type="frameshift">
<sequence resource="EMBL-CDS" id="AAA96658" version="1"/>
</conflict>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/INPPL1ID40984ch11q13.html"/>
</comment>
<dbReference type="EC" id="3.1.3.86" evidence="16 33 43"/>
<dbReference type="EMBL" id="L24444">
<property type="protein sequence ID" value="AAA50503.1"/>
<property type="status" value="ALT_FRAME"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="L36818">
<property type="protein sequence ID" value="AAA96658.1"/>
<property type="status" value="ALT_FRAME"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="Y14385">
<property type="protein sequence ID" value="CAA74743.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AP000593">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471076">
<property type="protein sequence ID" value="EAW74855.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC140853">
<property type="protein sequence ID" value="AAI40854.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS8213.1">
<molecule id="O15357-1"/>
</dbReference>
<dbReference type="PIR" id="JC5765">
<property type="entry name" value="JC5765"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001558.3">
<molecule id="O15357-1"/>
<property type="nucleotide sequence ID" value="NM_001567.3"/>
</dbReference>
<dbReference type="RefSeq" id="XP_011543301.1">
<molecule id="O15357-1"/>
<property type="nucleotide sequence ID" value="XM_011544999.2"/>
</dbReference>
<dbReference type="PDB" id="2K4P">
<property type="method" value="NMR"/>
<property type="chains" value="A=1194-1258"/>
</dbReference>
<dbReference type="PDB" id="2KSO">
<property type="method" value="NMR"/>
<property type="chains" value="B=1200-1258"/>
</dbReference>
<dbReference type="PDB" id="2MK2">
<property type="method" value="NMR"/>
<property type="chains" value="A=20-117"/>
</dbReference>
<dbReference type="PDB" id="3NR8">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A/B=419-732"/>
</dbReference>
<dbReference type="PDB" id="4A9C">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A/B=419-732"/>
</dbReference>
<dbReference type="PDB" id="5OKM">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.96"/>
<property type="chains" value="A/B/C/D/E/F/G/H=420-878"/>
</dbReference>
<dbReference type="PDB" id="5OKN">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.65"/>
<property type="chains" value="A/B/C/D/E/F/G/H=420-878"/>
</dbReference>
<dbReference type="PDB" id="5OKO">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.94"/>
<property type="chains" value="A/B=420-878"/>
</dbReference>
<dbReference type="PDB" id="5OKP">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.85"/>
<property type="chains" value="A=420-878"/>
</dbReference>
<dbReference type="PDBsum" id="2K4P"/>
<dbReference type="PDBsum" id="2KSO"/>
<dbReference type="PDBsum" id="2MK2"/>
<dbReference type="PDBsum" id="3NR8"/>
<dbReference type="PDBsum" id="4A9C"/>
<dbReference type="PDBsum" id="5OKM"/>
<dbReference type="PDBsum" id="5OKN"/>
<dbReference type="PDBsum" id="5OKO"/>
<dbReference type="PDBsum" id="5OKP"/>
<dbReference type="BMRB" id="O15357"/>
<dbReference type="SMR" id="O15357"/>
<dbReference type="BioGRID" id="109848">
<property type="interactions" value="122"/>
</dbReference>
<dbReference type="DIP" id="DIP-39733N"/>
<dbReference type="IntAct" id="O15357">
<property type="interactions" value="115"/>
</dbReference>
<dbReference type="MINT" id="O15357"/>
<dbReference type="STRING" id="9606.ENSP00000298229"/>
<dbReference type="BindingDB" id="O15357"/>
<dbReference type="ChEMBL" id="CHEMBL2331064"/>
<dbReference type="GuidetoPHARMACOLOGY" id="1459"/>
<dbReference type="SwissLipids" id="SLP:000000953"/>
<dbReference type="DEPOD" id="INPPL1"/>
<dbReference type="GlyGen" id="O15357">
<property type="glycosylation" value="1 site, 1 O-linked glycan (1 site)"/>
</dbReference>
<dbReference type="iPTMnet" id="O15357"/>
<dbReference type="MetOSite" id="O15357"/>
<dbReference type="PhosphoSitePlus" id="O15357"/>
<dbReference type="BioMuta" id="INPPL1"/>
<dbReference type="EPD" id="O15357"/>
<dbReference type="jPOST" id="O15357"/>
<dbReference type="MassIVE" id="O15357"/>
<dbReference type="MaxQB" id="O15357"/>
<dbReference type="PaxDb" id="O15357"/>
<dbReference type="PeptideAtlas" id="O15357"/>
<dbReference type="PRIDE" id="O15357"/>
<dbReference type="ProteomicsDB" id="48609">
<molecule id="O15357-1"/>
</dbReference>
<dbReference type="ProteomicsDB" id="48610">
<molecule id="O15357-2"/>
</dbReference>
<dbReference type="Antibodypedia" id="30825">
<property type="antibodies" value="336 antibodies"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000298229">
<molecule id="O15357-1"/>
<property type="protein sequence ID" value="ENSP00000298229"/>
<property type="gene ID" value="ENSG00000165458"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000538751">
<molecule id="O15357-2"/>
<property type="protein sequence ID" value="ENSP00000444619"/>
<property type="gene ID" value="ENSG00000165458"/>
</dbReference>
<dbReference type="GeneID" id="3636"/>
<dbReference type="KEGG" id="hsa:3636"/>
<dbReference type="UCSC" id="uc001osf.4">
<molecule id="O15357-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="3636"/>
<dbReference type="DisGeNET" id="3636"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000165458.13"/>
<dbReference type="GeneCards" id="INPPL1"/>
<dbReference type="HGNC" id="HGNC:6080">
<property type="gene designation" value="INPPL1"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000165458">
<property type="expression patterns" value="Low tissue specificity"/>
</dbReference>
<dbReference type="MalaCards" id="INPPL1"/>
<dbReference type="MIM" id="125853">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="258480">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="600829">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="neXtProt" id="NX_O15357"/>
<dbReference type="OpenTargets" id="ENSG00000165458"/>
<dbReference type="Orphanet" id="2746">
<property type="disease" value="Opsismodysplasia"/>
</dbReference>
<dbReference type="Orphanet" id="3144">
<property type="disease" value="Schneckenbecken dysplasia"/>
</dbReference>
<dbReference type="PharmGKB" id="PA29888"/>
<dbReference type="eggNOG" id="KOG0565">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="KOG4384">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00940000156576"/>
<dbReference type="HOGENOM" id="CLU_007493_1_1_1"/>
<dbReference type="InParanoid" id="O15357"/>
<dbReference type="KO" id="K15909"/>
<dbReference type="OMA" id="PCPQVGR"/>
<dbReference type="OrthoDB" id="311217at2759"/>
<dbReference type="PhylomeDB" id="O15357"/>
<dbReference type="TreeFam" id="TF323475"/>
<dbReference type="BioCyc" id="MetaCyc:HS09233-MONOMER"/>
<dbReference type="BRENDA" id="3.1.3.86">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="PathwayCommons" id="O15357"/>
<dbReference type="Reactome" id="R-HSA-1660499">
<property type="pathway name" value="Synthesis of PIPs at the plasma membrane"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1855204">
<property type="pathway name" value="Synthesis of IP3 and IP4 in the cytosol"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-912526">
<property type="pathway name" value="Interleukin receptor SHC signaling"/>
</dbReference>
<dbReference type="SABIO-RK" id="O15357"/>
<dbReference type="SignaLink" id="O15357"/>
<dbReference type="SIGNOR" id="O15357"/>
<dbReference type="BioGRID-ORCS" id="3636">
<property type="hits" value="13 hits in 880 CRISPR screens"/>
</dbReference>
<dbReference type="ChiTaRS" id="INPPL1">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="O15357"/>
<dbReference type="GeneWiki" id="INPPL1"/>
<dbReference type="GenomeRNAi" id="3636"/>
<dbReference type="Pharos" id="O15357">
<property type="development level" value="Tchem"/>
</dbReference>
<dbReference type="PRO" id="PR:O15357"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 11"/>
</dbReference>
<dbReference type="RNAct" id="O15357">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000165458">
<property type="expression patterns" value="Expressed in left lobe of thyroid gland and 203 other tissues"/>
</dbReference>
<dbReference type="ExpressionAtlas" id="O15357">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="O15357">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005856">
<property type="term" value="C:cytoskeleton"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0030175">
<property type="term" value="C:filopodium"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005794">
<property type="term" value="C:Golgi apparatus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0030027">
<property type="term" value="C:lamellipodium"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0016607">
<property type="term" value="C:nuclear speck"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0003779">
<property type="term" value="F:actin binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0016787">
<property type="term" value="F:hydrolase activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0042169">
<property type="term" value="F:SH2 domain binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0017124">
<property type="term" value="F:SH3 domain binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0007015">
<property type="term" value="P:actin filament organization"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007155">
<property type="term" value="P:cell adhesion"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0019221">
<property type="term" value="P:cytokine-mediated signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0001958">
<property type="term" value="P:endochondral ossification"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006897">
<property type="term" value="P:endocytosis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006006">
<property type="term" value="P:glucose metabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0002376">
<property type="term" value="P:immune system process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0043647">
<property type="term" value="P:inositol phosphate metabolic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0008285">
<property type="term" value="P:negative regulation of cell population proliferation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0010629">
<property type="term" value="P:negative regulation of gene expression"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006661">
<property type="term" value="P:phosphatidylinositol biosynthetic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0046856">
<property type="term" value="P:phosphatidylinositol dephosphorylation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0009791">
<property type="term" value="P:post-embryonic development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0032868">
<property type="term" value="P:response to insulin"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0097178">
<property type="term" value="P:ruffle assembly"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="Gene3D" id="1.10.150.50">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="3.30.505.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Gene3D" id="3.60.10.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR036691">
<property type="entry name" value="Endo/exonu/phosph_ase_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR005135">
<property type="entry name" value="Endo/exonuclease/phosphatase"/>
</dbReference>
<dbReference type="InterPro" id="IPR000300">
<property type="entry name" value="IPPc"/>
</dbReference>
<dbReference type="InterPro" id="IPR001660">
<property type="entry name" value="SAM"/>
</dbReference>
<dbReference type="InterPro" id="IPR013761">
<property type="entry name" value="SAM/pointed_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR000980">
<property type="entry name" value="SH2"/>
</dbReference>
<dbReference type="InterPro" id="IPR036860">
<property type="entry name" value="SH2_dom_sf"/>
</dbReference>
<dbReference type="Pfam" id="PF03372">
<property type="entry name" value="Exo_endo_phos"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00536">
<property type="entry name" value="SAM_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00017">
<property type="entry name" value="SH2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR00401">
<property type="entry name" value="SH2DOMAIN"/>
</dbReference>
<dbReference type="SMART" id="SM00128">
<property type="entry name" value="IPPc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00454">
<property type="entry name" value="SAM"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00252">
<property type="entry name" value="SH2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF47769">
<property type="entry name" value="SSF47769"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF55550">
<property type="entry name" value="SSF55550"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56219">
<property type="entry name" value="SSF56219"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50105">
<property type="entry name" value="SAM_DOMAIN"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50001">
<property type="entry name" value="SH2"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0009">Actin-binding</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0130">Cell adhesion</keyword>
<keyword id="KW-0966">Cell projection</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0206">Cytoskeleton</keyword>
<keyword id="KW-0219">Diabetes mellitus</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0378">Hydrolase</keyword>
<keyword id="KW-0391">Immunity</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0727">SH2 domain</keyword>
<keyword id="KW-0729">SH3-binding</keyword>
<feature type="chain" description="Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2" id="PRO_0000302870">
<location>
<begin position="1"/>
<end position="1258"/>
</location>
</feature>
<feature type="domain" description="SH2" evidence="15">
<location>
<begin position="21"/>
<end position="117"/>
</location>
</feature>
<feature type="domain" description="SAM" evidence="14">
<location>
<begin position="1196"/>
<end position="1258"/>
</location>
</feature>
<feature type="short sequence motif" description="SH3-binding">
<location>
<begin position="944"/>
<end position="949"/>
</location>
</feature>
<feature type="short sequence motif" description="NPXY motif">
<location>
<begin position="983"/>
<end position="986"/>
</location>
</feature>
<feature type="compositionally biased region" description="Pro-rich">
<location>
<begin position="935"/>
<end position="1105"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10">
<location>
<position position="132"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine" evidence="8">
<location>
<position position="165"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="8 9">
<location>
<position position="241"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10">
<location>
<position position="352"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="10">
<location>
<position position="886"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10">
<location>
<position position="890"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine" evidence="10 35">
<location>
<position position="958"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by SRC" evidence="19 23">
<location>
<position position="986"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10">
<location>
<position position="1131"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="7 10">
<location>
<position position="1135"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="10 20">
<location>
<position position="1162"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="10">
<location>
<position position="1257"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_027985" evidence="45">
<location>
<begin position="1"/>
<end position="242"/>
</location>
</feature>
<feature type="sequence variant" description="In OPSMD; dbSNP:rs397514511." id="VAR_069586" evidence="40">
<original>R</original>
<variation>W</variation>
<location>
<position position="401"/>
</location>
</feature>
<feature type="sequence variant" description="Associated with susceptibility to NIDDM; dbSNP:rs61749195." id="VAR_034980" evidence="30">
<original>L</original>
<variation>I</variation>
<location>
<position position="632"/>
</location>
</feature>
<feature type="sequence variant" description="In OPSMD; dbSNP:rs397514510." id="VAR_069587" evidence="40">
<original>P</original>
<variation>S</variation>
<location>
<position position="659"/>
</location>
</feature>
<feature type="sequence variant" description="In OPSMD." id="VAR_069588" evidence="40">
<original>W</original>
<variation>C</variation>
<location>
<position position="688"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs116848359." id="VAR_034981" evidence="30">
<original>V</original>
<variation>M</variation>
<location>
<position position="721"/>
</location>
</feature>
<feature type="sequence variant" description="In OPSMD; dbSNP:rs397514512." id="VAR_069589" evidence="40">
<original>F</original>
<variation>I</variation>
<location>
<position position="722"/>
</location>
</feature>
<feature type="sequence variant" description="Associated with susceptibility to NIDDM; dbSNP:rs70940821." id="VAR_034982" evidence="30">
<original>N</original>
<variation>S</variation>
<location>
<position position="982"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs11548491." id="VAR_034983" evidence="30">
<original>A</original>
<variation>G</variation>
<location>
<position position="1083"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1049472." id="VAR_034984" evidence="28 42 44">
<original>A</original>
<variation>G</variation>
<location>
<position position="1114"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with p130Cas/BCAR1 and its ability to induce increased adhesion. Abolishes phosphorylation upon FCGR2A clustering." evidence="18 26">
<original>R</original>
<variation>G</variation>
<location>
<position position="47"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes interaction with SH3YL1." evidence="39">
<original>PL</original>
<variation>AA</variation>
<location>
<begin position="140"/>
<end position="141"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes enzyme activity but not phosphorylation upon FCGR2A clustering." evidence="26">
<original>D</original>
<variation>A</variation>
<location>
<position position="607"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces PDGF-stimulated tyrosine phosphorylation and association with SHC1." evidence="35">
<original>T</original>
<variation>A</variation>
<location>
<position position="958"/>
</location>
</feature>
<feature type="mutagenesis site" description="Inducer a strong reduction of phosphorylation upon re-plating on collagen I." evidence="23">
<original>YY</original>
<variation>FF</variation>
<location>
<begin position="986"/>
<end position="987"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; AAA96658." ref="1" evidence="46">
<original>I</original>
<variation>M</variation>
<location>
<position position="307"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 1; AAA50503/AAA96658." ref="1" evidence="46">
<original>R</original>
<variation>A</variation>
<location>
<position position="1142"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="21"/>
<end position="23"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="28"/>
<end position="38"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="41"/>
<end position="48"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="56"/>
<end position="61"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="66"/>
<end position="72"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="75"/>
<end position="77"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="79"/>
<end position="81"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="85"/>
<end position="87"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="91"/>
<end position="94"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="95"/>
<end position="102"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="422"/>
<end position="432"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="443"/>
<end position="446"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="450"/>
<end position="453"/>
</location>
</feature>
<feature type="turn" evidence="6">
<location>
<begin position="458"/>
<end position="460"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="465"/>
<end position="473"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="478"/>
<end position="493"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="498"/>
<end position="505"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="508"/>
<end position="514"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="516"/>
<end position="521"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="522"/>
<end position="531"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="538"/>
<end position="550"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="553"/>
<end position="561"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="569"/>
<end position="582"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="588"/>
<end position="592"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="595"/>
<end position="597"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="599"/>
<end position="607"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="612"/>
<end position="614"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="616"/>
<end position="624"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="629"/>
<end position="632"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="636"/>
<end position="642"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="645"/>
<end position="647"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="675"/>
<end position="677"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="680"/>
<end position="682"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="690"/>
<end position="696"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="702"/>
<end position="709"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="715"/>
<end position="718"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="721"/>
<end position="728"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="732"/>
<end position="734"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="747"/>
<end position="758"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="765"/>
<end position="770"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="774"/>
<end position="776"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="784"/>
<end position="787"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="793"/>
<end position="799"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="800"/>
<end position="802"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="813"/>
<end position="816"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="820"/>
<end position="827"/>
</location>
</feature>
<feature type="turn" evidence="6">
<location>
<begin position="828"/>
<end position="830"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="833"/>
<end position="841"/>
</location>
</feature>
<feature type="turn" evidence="6">
<location>
<begin position="842"/>
<end position="844"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="845"/>
<end position="848"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="850"/>
<end position="858"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="861"/>
<end position="873"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="1202"/>
<end position="1206"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="1207"/>
<end position="1209"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="1211"/>
<end position="1213"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="1214"/>
<end position="1218"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="1219"/>
<end position="1221"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="1225"/>
<end position="1228"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="1233"/>
<end position="1238"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="1244"/>
<end position="1256"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2K4P"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2MK2"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4A9C"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5OKM"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5OKO"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5OKP"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="17081983"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="18669648"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="20068231"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000250"/>
<evidence key="12" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="D7PF45"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q6P549"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00184"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00191"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10194451"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11016922"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11158326"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11349134"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11687594"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11739414"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12086927"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12235291"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12504111"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12676785"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12690104"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15220217"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15668240"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15687335"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15735664"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16302969"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16824732"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17135240"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17219406"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17314030"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17557929"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20933011"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21624956"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23273569"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8530088"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9367831"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9660833"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source ref="4"/>
</evidence>
<evidence key="45" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="8530088"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000305"/>
<evidence key="47" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="10194451"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="16824732"/>
</source>
</evidence>
<sequence length="1258" mass="138599" checksum="D76B5AA8ACDE8CBA" modified="2009-11-24" version="2">MASACGAPGPGGALGSQAPSWYHRDLSRAAAEELLARAGRDGSFLVRDSESVAGAFALCVLYQKHVHTYRILPDGEDFLAVQTSQGVPVRRFQTLGELIGLYAQPNQGLVCALLLPVEGEREPDPPDDRDASDGEDEKPPLPPRSGSTSISAPTGPSSPLPAPETPTAPAAESAPNGLSTVSHDYLKGSYGLDLEAVRGGASHLPHLTRTLATSCRRLHSEVDKVLSGLEILSKVFDQQSSPMVTRLLQQQNLPQTGEQELESLVLKLSVLKDFLSGIQKKALKALQDMSSTAPPAPQPSTRKAKTIPVQAFEVKLDVTLGDLTKIGKSQKFTLSVDVEGGRLVLLRRQRDSQEDWTTFTHDRIRQLIKSQRVQNKLGVVFEKEKDRTQRKDFIFVSARKREAFCQLLQLMKNKHSKQDEPDMISVFIGTWNMGSVPPPKNVTSWFTSKGLGKTLDEVTVTIPHDIYVFGTQENSVGDREWLDLLRGGLKELTDLDYRPIAMQSLWNIKVAVLVKPEHENRISHVSTSSVKTGIANTLGNKGAVGVSFMFNGTSFGFVNCHLTSGNEKTARRNQNYLDILRLLSLGDRQLNAFDISLRFTHLFWFGDLNYRLDMDIQEILNYISRKEFEPLLRVDQLNLEREKHKVFLRFSEEEISFPPTYRYERGSRDTYAWHKQKPTGVRTNVPSWCDRILWKSYPETHIICNSYGCTDDIVTSDHSPVFGTFEVGVTSQFISKKGLSKTSDQAYIEFESIEAIVKTASRTKFFIEFYSTCLEEYKKSFENDAQSSDNINFLKVQWSSRQLPTLKPILADIEYLQDQHLLLTVKSMDGYESYGECVVALKSMIGSTAQQFLTFLSHRGEETGNIRGSMKVRVPTERLGTRERLYEWISIDKDEAGAKSKAPSVSRGSQEPRSGSRKPAFTEASCPLSRLFEEPEKPPPTGRPPAPPRAAPREEPLTPRLKPEGAPEPEGVAAPPPKNSFNNPAYYVLEGVPHQLLPPEPPSPARAPVPSATKNKVAITVPAPQLGHHRHPRVGEGSSSDEESGGTLPPPDFPPPPLPDSAIFLPPSLDPLPGPVVRGRGGAEARGPPPPKAHPRPPLPPGPSPASTFLGEVASGDDRSCSVLQMAKTLSEVDYAPAGPARSALLPGPLELQPPRGLPSDYGRPLSFPPPRIRESIQEDLAEEAPCLQGGRASGLGEAGMSAWLRAIGLERYEEGLVHNGWDDLEFLSDITEEDLEEAGVQDPAHKRLLLDTLQLSK</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>

